Drug firm Lupin on Thursday said it has received an approval from the U.S. health regulator to market a generic non-steroidal anti-inflammatory drug in the American market.
The company has received an approval from the U.S. Food and Drug Administration for Diclofenac Sodium Topical Solution, Lupin said in a statement.
The company's product is a generic equivalent of Horizon Pharma's Pennsaid Topical Solution, it added.
The product will be manufactured at Lupin's facility in Pithampur, Madhya Pradesh.
As per IQVIA MAT June 2022 data, Diclofenac Sodium Topical Solution had estimated annual sales of $484 million in the U.S.
Shares of Lupin on Thursday ended 0.23% up at Rs 662.70 apiece on the BSE.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
